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Gold nanoparticles approach to 
detect chondroitin sulphate and 
hyaluronic acid urothelial coating
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Gabriele Brecchia1, Cecilia Dall’Aglio  1, Rolando Arcelli1, Giovanni Cochetti3, Andrea Boni3 & 
Ettore Mearini3
This study investigated the location of hyaluronic acid (HA)- and chondroitin sulphate (CS)-coated gold 
nanoparticles in rabbit bladder and evaluated gene expression of CD44, RHAMM and ICAM-1 receptors 
involved in HA and CS transport into the cell. Gold nanoparticles were synthesised by reduction of gold 
salts with HA or CS to form HA-AuNPs and CS-AuNPs. Bladder samples were incubated with CS-AuNPs 
and HA-AuNPs or without glycosaminoglycans. Transmission electron microscopy, optic microscopy 
and scanning electron microscopy were used to determine the location of the synthesised AuNPs. 
Real-time PCR was used to analyse expression of urothelial cell receptors CD44, RHAMM, ICAM-1, after 
ex vivo administration of CS-AuNPs and HA-AuNPs. We showed that HA-AuNPs and CS-AuNPs were 
located in the cytoplasm and tight junctions of urothelial umbrella cells; this appearance was absent in 
untreated bladders. There were no significant differences in gene expression levels for CD44, RHAMM 
and ICAM-1 receptors in treated versus control bladder tissues. In conclusion, we clearly showed the 
presence of exogenous GAGs in the bladder surface and the tight junctions between umbrella cells, 
which is important in the regeneration pathway of the urothelium. The GAGs-AuNPs offer a promising 
approach to understanding the biophysical properties and imaging of urothelial tissue.
Bladder epithelium, also known as urothelium or transitional epithelium, is a highly specialised tissue that plays 
a key role in the defence of the bladder wall against various toxins. The urothelium is coated in a thick layer of 
glycosaminoglycans (GAGs) that acts as a non-specific anti-adherence factor and protects against infection1. This 
GAG layer is embedded in a network of proteins, forming the so-called glycocalyx2. Although the function of 
this layer is not yet fully understood, it has been suggested that it forms a physical barrier with hydro-repellent 
properties that protects epithelial cells against the irritative effects of urine components3. In fact, the high density 
of GAGs allows water molecules to form a surface impenetrable to many low molecular weight solutes4. There 
is strong evidence that an absence of GAGs is linked to loss of normal urothelial function. This loss of function 
results in “storage symptoms” such as frequency, which is an innate protective mechanism designed to minimise 
contact between urine and the damaged bladder wall5.
Hyaluronic acid (HA) and chondroitin sulphate (CS) are two naturally occurring GAGs abundantly present 
on bladder urothelium6. Many of the effects of HA are mediated through cell surface receptors, three of which 
have been molecularly characterised, namely cluster of differentiation 44 (CD44), hyaluronan-mediated motil-
ity receptor (HMMR), also known as RHAMM, and intercellular adhesion molecule-1 (ICAM-1)7. Although 
CD44 is the principal HA receptor, it also shows an affinity for CS8. The CD44 affinity of these polymers has 
resulted in the development of several nanoparticles for cancer targeting9 and bulk hydrogel scaffolds for tissue 
engineering10.
Administration of exogenous GAGs is widely accepted as therapy in various bladder disorders11, 12. Intravesical 
instillation of HA and CS shows promise as a treatment for some bladder diseases, by promoting regeneration 
of GAG in the bladder urothelium13, 14. However, data are lacking regarding the localisation of these molecules 
within the urothelium and the extent of their integration to cells or tissues.
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In order to improve the detectability of these molecules in tissue samples, we have engineered HA-and 
CS-coated gold nanoparticles (AuNPs)15, which have unique surface plasma resonance and optical properties16. 
In this study, we investigated the location of HA and CS after ex vivo incubation of rabbit bladder tissue with 
HA-AuNPs and CS-AuNPs to determine whether the benefits of HA and CS replacement therapy might be due 
to coating of the urothelium with GAGs. In addition, we evaluated relative gene expression of receptors involved 
in HA and CS transport into the cell (CD44, RHAMM and ICAM-1) in order to understand whether incubation 
with GAG nanoparticles modifies receptor expression.
Materials and Methods
Ethics Statement. The procedures involving the animals and their care were conducted in conformity with 
the national and international laws and policies. Animal protocols were reviewed and approved by the Animal 
Committee of the University of Perugia, Italy, and followed the guidelines for the care and use of animals at our 
institution (Comitato Universitario di Bioetica, permit number 129/2016-PR). All rabbits used for the study were 
provided by Centro Servizi per la ricerca pre-clinica (Perugia, Italy). All the animals were housed in each cage and 
fed with water and food ad libitum.
Synthesis of CS and HA coated AuNPs. CS 38 kDa and HA 1500 kDa were provided by IBSA, Italy. 
This particular molecular weight HA was chosen to best mimic in vivo conditions. Gold chloride and NaBH4 
were purchased from Sigma-Aldrich. HA-AuNPs and CS-AuNPs were synthesised using the NaBH4 reduction 
method, as described by Tengdelius et al.17 with slight modifications. Briefly, gold chloride was dissolved in 10 mL 
of deionised water and refluxed for two hours then cooled to 60 °C. CS 30 mg (1 equivalent with respect to disac-
charide units) was dissolved separately in 10 mL of deionised water. For the synthesis of HA-coated AuNPs, 24 mg 
(1 equivalent with respect to disaccharide units) of HA was used. The HA or CS solution was added to the gold 
solution (kept at 60 °C) and NaBH4 (4.56 mg, 0.12 mmol, 2 equivalents) was added. The reaction was left to pro-
gress for 8 hours at 60 °C and the formation of NP was observed immediately as the colour changed to deep 
violet. Thereafter, the CS-AuNP and HA-AuNP solutions were loaded into a dialysis bag (MWCO 3500), dialysed 
against deionised water (4 × 2 L) for 48 h and lyophilised to obtain 30 mg of CS-AuNPs or 25 mg of HA-AuNPs. 
The compounds were stored at room temperature and before use were re-suspended in water at a final concen-
tration of 1 mg/mL.
Synthesis of BSA-AuNP. BSA-AuNP used as a control in the study was obtained by incubating commer-
cially available citrate coated gold nanoparticles (40 nm, from EY Laboratories, Inc.) with BSA following the 
reported protocol18. The concentration of BSA used for coating was same as the two GAGs used to synthesize HA 
and CS AuNPs.
Nanoparticle characterisation. CS-AuNPs and HA-AuNPs were monitored using spectrophotomet-
ric measurements (Evolution 201 UV VIS; Thermo Fisher). Transmission electron microscopy (TEM; Philips 
EM 208 equipped with a digital camera) measurements were made from samples prepared by placing drops of 
the gold NP dispersions on carbon-coated TEM copper grids (Società Italiana Chimici-Roma); mixtures were 
allowed to dry for 1 minute then excess solution was removed using blotting paper. Dynamic light scattering 
(DLS) measurements were carried out using Malvern’s Zetasizer Nano ZS instrument.
Animals and tissue preparation. Eighteen 8-week-old healthy New Zealand female White rab-
bits (≈1500 ± 200 g) were used in the study. Animals were sedated with 0.2 mg/kg medetomidine (Medetor; 
VirbacSrl) and 10 mg/kg intramuscular ketamine (Inoketam; VirbacSrl) and anaesthetised with 5% isofluorane. 
Rabbits were euthanised by injection of 200 mL ketamine/xylazine until breathing stopped. Bladders were har-
vested (weighing 5–6 g) and washed extensively with sterile phosphate-buffered saline (PBS) supplemented with 
penicillin 200 U/mL, streptomycin 200 mg/mL, and amphotericin-B 12.5 mg/mL (Sigma-Aldrich; St. Louis, 
USA) to remove debris. Tissue was then placed in 5 mL of Dulbecco’s Modified Eagle Medium (DMEM, Gibco; 
Gaithersburg, USA), 10% foetal bovine serum (Gibco, Gaithersburg, USA), penicillin 10,000 U/mL, streptomycin 
10 µg/mL and amphotericin-B 10 µg/mL.
GAGs treatment. Twelve rabbit bladder sections (weighing 0.7 to 0.9 g) were incubated with 500 µL of 
CS-AuNPs (1 mg/mL) and 500 µL of HA-AuNPs (1 mg/mL) at 37 °C for 60 minutes; the other six samples received 
the same treatment but were incubated with colloidal gold solution adsorbed with bovine serum albumin instead 
of GAGs (BSA-AuNPs; control). The 60-minute incubation time was adopted as during this time, no significant 
necrosis or cell degeneration as observed.
Sample preparation for microscopy. Bladder samples for optical microscopy were fixed by immersion 
in 2.5% glutaraldehyde in 0.1 M PBS at room temperature for 24 hours. Then the tissue samples were dehydrated 
through a graded series of ethanol, cleared in xylene and embedded in paraffin. Sections were processed for a 
better identification of the bladder epithelium using haematoxylin-eosin (HE) staining (Sigma-Aldrich, St. Louis, 
Mo, USA).
For scanning electron microscopy (SEM; Philips XL 30 resolution: 2.0 nm at 30 kV and 10 mbar water vapour), 
small bladder samples were fixed in 2.5% glutaraldehyde in distilled water for 2 hours at room temperature. 
Samples were washed in distilled water for 20 minutes, and dehydrated through ascending grades ethanol, accord-
ing to the critical point drier method. Dried specimens were mounted on stubs with silver paste and sputtered 
with gold (200–250 nm) by cathode atomisation under vacuum.
For TEM, small samples of bladder tissue were placed in 2.5% glutaraldehyde added to 0.1 M PBS, pH 7.3, for 
3 hours at room temperature. After rinsing twice in PBS, the specimens were post-fixed in 1% buffered osmium 
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tetroxide at pH 7.2 for 3 hours at 4 °C. Samples were then dehydrated, pre-infiltrated and embedded in Epon 812. 
Semi-thin sections (1 µm) were obtained and stained with methylene blue and Azur blue II19 and examined under 
a light microscope to identify the best specimens. Ultrathin sections were mounted on 200-mesh copper grids, 
stained with uranyl acetate and lead citrate20.
Evaluation of receptor RNA expression. RNA was extracted from 5 µm paraffin-embedded bladder 
sections adjacent to that observed using optical microscopy. Extraction was performed with a commercial kit 
(RecoverAll Total Nucleic Acid Isolation Kit; Ambion, Austin, USA) following the manufacturer’s instructions. 
Total RNA was quantified with a fluorometer (Qubit 2.0, Invitrogen, Carlsbad, USA). About 20 ng of total RNA 
were reverse transcribed (RT) in 20 µL of iSCRIPTcDNA (BioRad; Hercules, USA) using random hexamers. 
No-RT controls were included to check for genomic DNA contamination.
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was carried out with 5 μL of a ten-fold 
diluted cDNA in a final volume of 25 μL using 10 μL of SsoFast™ EvaGreen1 Supermix (BioRad; Hercules, USA). 
Primers for CD44, RHAMM and ICAM-1 were commercially purchased (PrimePCRSyberGreen Assay, Bio-Rad; 
Hercules, CA, USA).
All PCR reactions (Bio-Rad iCycler Real-Time PCR) had an initial incubation at 95 °C for 15 minutes, fol-
lowed by 45 cycles at 95 °C for 15 seconds and 60 °C for 1 minute, during which fluorescence data were collected. 
Each sample was run in triplicate and the results were averaged. Sample amplification fidelity was verified by 
agarose gel electrophoresis. 18 S rRNA was used as an endogenous control to normalise variations in the amount 
of starting RNA samples as previously reported21. For each PCR run, no template controls and no-RT controls 
were included in order to ascertain the absence of gDNA.
The 2−ΔΔCt method was used to calculate the relative expression of the target genes as follows22:
− − −−2 ((C target C 18S) (C control C 18S))t t t t
Statistical analysis. Results are presented as mean ± standard error (SE). Statistical comparisons between 
groups were performed using unpaired t-test. Significance was set at p ≤ 0.05. All analyses were performed in 
GraphPad Prism version 6.00.
Results
GAGs-AuNPs evaluation. GAGs-AuNPs displayed a UV-Vis analysis at λ max 546 nm (HA) and 520 (CS) 
single surface plasma resonance, suggesting formation of spherical morphology (Fig. 1).
DLS analysis indicated that for HA-AuNPs 89% nanoparticles had a size of 98 ± 18 nm, while a zeta potential 
(Zp) = −36.5 ± 5 mV, and for CS-AuNPs 99.4% nanoparticles had a size of 58 ± 12, with a Zp = −23.5 ± 4 mV. 
On the contrary, TEM analysis indicated a 40 ± 1.5 nm and 19 ± 0.6 nm radius, for HA-AuNPs and CS-AuNPs 
respectively, as Fig. 2 shows.
The higher hydrodynamic size of the nanoparticles as determined by DLS are attributed to the hydration of 
GAG coat, which is not discernible in the TEM measurements.
Microscopy evaluations. After ex vivo incubation, SEM observations showed the vast majority of epithelial 
cells with a scalloped luminal face being covered by some ridges of GAGs-AuNPs (Fig. 3). This appearance was 
absent in untreated bladders (Fig. 4).
TEM analysis showed some particles of GAGs-AuNPs behind plasma membranes of apex line cells of the 
bladder epithelium (Fig. 5). In particular, some GAGs-AuNPs were evident in the cytoplasm (Figs 6 and 7), sug-
gesting that nanoparticles can enter inside the cells, overcoming the plasma membrane barrier, and localise on 
the membranes of cytoplasmic organelles.
PCR assessment. Single peaks in the melting curves confirmed the uniqueness of PCR products. There 
were no statistically significant differences in receptor gene expression in bladders incubated with HA-AuNP and 
CS-AuNP compared with control. The ICAM-1gene showed the highest mRNA expression level in treated group 
Figure 1. Gold colloids absorption spectrum with a peak at 546 nm for HA-AuNP (blu) and at 520 for CS-
AuNP (red), showing how the reaction proceeds. This measurement establishes the optimum conditions for the 
preparation of gold colloids.
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Figure 2. Transition electron microscopy (TEM) image showed both GAGs-AuNPs (19 to 40 nm), re-dispersed 
in water and deposited in the form of films onto carbon-coated TEM grids.
Figure 3. Scanning electron microscopy (SEM) image of treated bladder epithelium showing GAGs-AuNPs 
(arrow) linked to the plasma membranes of epithelial cells
Figure 4. Scanning electron microscopy (SEM) image of untreated (control) bladder epithelium showing an 
absence of any visible aggregates.
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(1.83 ± 1.23) vs control (1.82 ± 0.56) while CD44 and HMMR gene expression in treated samples (0.74 ± 0.28 and 
0.15 ± 0.05) were lower than those in control samples (0.56 ± 0.10 and 0.06 ± 0.02) (Fig. 8).
Discussion
This study showed the presence of exogenous GAGs in bladder umbrella cells after ex vivo incubation of samples 
with gold nanoparticles containing CS and HA. No change in GAG receptor expression levels was detected in 
treated bladders.
The rabbit bladder is a good model for investigating the physiological, histological, and biochemical prop-
erties of the functioning human bladder23. Similarities include similar receptor distribution in the urinary tract 
and comparable pharmacological responses to a wide variety of agents24. The use of rabbit bladders offers several 
advantages, including availability of samples and transport of bladder tissue, and fewer ethical issues problems 
compared with the use of bladders from other species (e.g. dogs, pigs or humans).
We investigated the location of HA- and CS-coated gold nanoparticles in rabbit bladder tissue in order to 
demonstrate that the mechanism of action of GAGs replacement therapy is presumed to be due to a real coating 
of the bladder surface to replace physiological HA and CS lost as a result of disease. AuNPs are emerging as a very 
useful tool due to their unique electronic, optical, and catalytic properties, with simple synthesis, good stability 
Figure 5. Transition electron microscopy (TEM) image showing GAGs-AuNPs linked to the plasma membrane 
of epithelial cells (arrows).
Figure 6. Transition electron microscopy (TEM) image showing GAGs-AuNPs linked to the plasma membrane 
of epithelial cells with some particles localised in the cytoplasm (arrows).
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and chemical inertness compared with other nanocarriers25. GAGs molecules with the sulphated polyanionic 
structure stabilise AuNPs in aqueous solution, thus improving biocompatibility of the metal15.
A GAG layer covers the umbrella cells and contributes to urothelial barrier function, also reducing the adhe-
sion of many urinary bacterial pathogens. Furthermore, several events originating from intravesical GAG injury 
may result in chronic damage to the bladder epithelium and prevent healing due to direct contact of abnormal uri-
nary constituents with the subepithelial layer. Prompt restoration of the GAG layer to prevent the inflammatory 
cycle is a rationale underlying treatment of chronic cystitis and painful bladder syndrome/interstitial cystitis26. 
“GAG replacement therapy” is effective in many patients, as shown in several models of urothelial damage, show-
ing strong surface binding11. Another treatment option, based on endocavital GAG replenishment therapy has 
been shown to improve urinary irritative symptoms secondary to pelvic radiation therapy (RT)27, and to have 
potential as prophylactic therapy in this setting28. RT stimulates a neuroinflammatory cascade with activation 
Figure 7. Transition electron microscopy (TEM) image showing GAGs-AuNPs linked to the plasma membrane 
of epithelial cells with some particles localised in the cytoplasm nearest to cellular membranous structures.
Figure 8. Light microphotograph (A) with haematoxylin and eosin (HE) stain showing histologic evaluation 
of rabbit bladder (Top to base: umbrella, intermediate and basal cells; arrows show the typical “dome-shaped” 
apical cells). Normalized expression value 2−ΔΔCt (mean ± standard error) (B) of CD44, RHAMM and ICAM-1 
in bladder tissues incubated with HA-AuNP and CS-AuNP (left box for each type of receptor) and control 
bladder tissues incubated with BSA-AuNPs solution (dashed line).
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of mast cell and release of histamine that could be inhibited by HA, while CS promotes regeneration of the AG 
layer27.
This study clearly showed the presence of exogenous GAGs in tight junctions and in the cytoplasm of umbrella 
cells. This is particularly important if we consider the regeneration pathway of the urothelium. In fact, within 
a few days of urothelial damage, tight junctions begin to develop between intermediate cells, increasing the 
water-tightness of the new layer. In this sense, the early or prophylactic administration of exogenous GAGs could 
play an important role in the rapid restoration of the urothelial impermeability29. In particular, the tight junction 
plays a leading role in the establishment of the transepithelial resistances, thus blocking ion flux within the epithe-
lium. We also showed that HA and CS were able to penetrate into umbrella cells, which prompted us to evaluate 
intracellular signal transduction pathways using real-time PCR. Most of the effects of HA are mediated through 
CD44, RHAMM, and ICAM-1. Binding of the HA ligand to its receptors can direct cell trafficking during phys-
iological and pathological events30. Our aim was also to demonstrate that the entry of HA and CS into umbrella 
cells is not associated with an increase in expression of CD44, RHAMM, and ICAM-1, and this was indeed the 
case. Southgate and colleagues31 reported CD44 expression in the basal layer of normal human urothelium that 
progressed from the basal to the superficial layer, where expression was lost. Similar CD44 expression profiling 
has been portrayed in rabbit bladder32. Further studies are warranted to facilitate understanding of the role of 
CD44, RHAMM, and ICAM-1 in the transitional epithelium.
A limitation of this research is that the microscopy analysis of GAG-AuNPs has only a qualitative value. As a 
result, we can only confirm the presence (not the quality) of GAGs-AuNPs on the urothelial mucosa. In addition, 
our aim was to investigate receptors on the surface of the urothelial cells and therefore we do not have informa-
tion on the mechanism of uptake of GAG-AuNPs.
Conclusions
This study clearly shows not only the presence of exogenous GAGs in the bladder surface but also in the tight 
junctions between umbrella cells, which is important in the regeneration pathway of the urothelium. Based on 
our findings, the entry of GAGs into urothelial cells does not seem to alter their receptor gene expression. The 
GAGs-AuNPs offer a promising approach to understanding the biophysical properties and imaging of urothe-
lial tissue. In future, we will validate these results in an in vivo rabbit model and evaluate the administration of 
GAGs as a polymer and as AuNPs in an experimental model of cystitis, in order to study GAG-related molecular 
processes.
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